On July 6, Sino Biopharmaceutical rose 3.38% in regular trading, trading at HK$5.02/share, with turnover of HK$126 million. The gain extends a multi-day rally fueled by dual catalysts from late last week.

On the news front, the company announced on July 3 that its subsidiary Beijing Tide Pharmaceutical's new drug application for ropivacaine hydrochloride sustained-release solution was accepted by China's National Medical Products Administration, intended as a postoperative long-acting analgesic for adults. This marks another pipeline milestone following the NDA acceptance of tecotabart vedotin for gastric cancer and the marketing approval of Peceleganan Spray for wound infections in late June.

Meanwhile, the broader innovative pharmaceutical sector continues to benefit from the National Healthcare Security Administration's publication of the preliminary review results for the basic medical insurance and commercial health insurance innovative drug catalog adjustments. The review showed a 92% pass rate, up 8 percentage points year-over-year, with a newly introduced pre-application mechanism further demonstrating policy support for innovative drugs. CITIC Construction Investment expressed optimism on medical insurance access and commercial insurance incremental opportunities for related innovative drug companies.

Within the Pharmaceuticals sector, CSPC Pharma rose 3.88%, Hansoh Pharma rose 2.31%, Haixi Pharma rose 9.63%, Hengrui Pharma rose 2.09%, and Luye Pharma rose 2.96%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)